1. Introduction {#sec1}
===============

Fatigue is a common complaint among older adults. While it is often a symptom of psychiatric or medical illness, for many older persons, it is not possible to identify the underlying cause. Studies during the last 15 years have consistently shown that fatigue in older adults is a strong predictor of functional limitations \[[@B1]\], disability \[[@B2]\], and mortality \[[@B3]\]. Thus, fatigue might represent an early stage of frailty, defined as a physiologic state of increased vulnerability to stressors that results from decreased reserves in multiple physiologic and biologic systems \[[@B4]\].

Cellular and organismal damages caused by an accruing burden of oxidative stress could be an underlying factor to fatigue. Increased oxidative stress can be caused by defective mitochondria as well as by chronic low-grade inflammation. Both these conditions are known to be associated with increasing age, and evidence suggests that oxidative stress and inflammation are associated with frailty \[[@B5]\].

It is generally accepted that oxidative stress and inflammation are important contributors to the pathology of aging-related diseases such as cardiovascular disease \[[@B6]\], dementia \[[@B7]\], and cancer \[[@B8]\]. Such conditions often predispose to frailty \[[@B4]\]. Leukocyte telomere length (LTL) ostensibly undergoes an accelerated shortening due to inflammation and increased oxidative stress \[[@B6], [@B9]\]. This might explain the association of shortened LTL with aging-related diseases and some of their risk factors, including coronary heart disease, dementia, and insulin resistance \[[@B10], [@B11]\].

Potentially, shortened LTL and the consequent cellular aging could thus be an underlying mechanism to fatigue.

Woo et al. \[[@B12]\] found no apparent association between LTL and frailty in a study that applied a composite frailty index score but had not examined directly the potential connection between LTL and fatigue. To examine whether a link in fact exists between LTL and fatigue, we have exploited the same-sex twin design that has previously made it possible to show relationsships of LTL with mortality \[[@B13]\], and physical ability \[[@B14]\]. In the present study we show results supporting the association between LTL and fatigue.

2. Material and Methods {#sec2}
=======================

2.1. Description of Twin Sample {#sec2.1}
-------------------------------

The Longitudinal Study of Aging Danish Twins (LSADT) began in 1995 with an assessment of same-sex twin pairs born in Denmark before 1920 \[[@B15]\]. Since 1995 twins from the LSADT have participated in a comprehensive face-to-face interview including detailed questions about health, lifestyle, and physical functioning \[[@B16]\]. This interview has been repeated every second year for a total of six examinations. At the second examination, blood samples were collected from 283 twin pairs. Of these, a total of 274 pairs (548 individuals) had their LTL measured \[[@B13]\].

For this study, the population was restricted to the 439 individuals who were nondisabled, that is, who were able to rise from a chair or bed, walk indoors, get outdoors, walk outdoors in nice weather, walk outdoors in bad weather, and climb stairs without help. Further, we excluded persons who had answered the questionnaire by a proxy. These restrictions were applied as previous studies have shown fatigue to be related to onset of disability \[[@B2]\], functional limitations \[[@B1]\], and even cardiovascular disease \[[@B17]\] among nondisabled and nondiseased. We also repeat the analyses in a restricted sample of persons below 80 years, as these persons are more likely to be without conditions, which we have not been able to adjust for.

For further information on the participants, see [Table 1](#tab1){ref-type="table"}.

The study has been approved by the local scientific-ethical Committee. All participants provided written informed consent.

2.2. LTL Measurement {#sec2.2}
--------------------

Leukocyte DNA was extracted using standard techniques. DNA quality was assessed by electrophoresis. LTL was measured using Southern blots of the terminal restriction fragments after digestion with HphI and MnlI restriction enzymes; for 377 of the nondisabled twins the terminal restriction fragments were also generated by HinfI and RsaI digestion \[[@B18]\]. The HphI/MnlI products include predominantly true telomeric repeats, whereas the HinfI/RsaI product includes a proximal telomere segment that is not strictly TTAGGG. The HphI/MnlI products were on average 1.1 kb shorter than the HinfI/RsaI products, and the two LTL measures correlated strongly (*r* = 0.88, *P* \< 0.001).

Samples from the cotwins in each twin pair were resolved in adjacent lanes of the same gel. Running DNA digests from the two cotwins in adjacent lanes on the same gel diminished the methodological variation within twin-pairs. In between-pair analysis the "gel effect" was included as covariate.

Each sample was measured in duplicate (performed on different gels) and the mean of the two samples was used. The interassay coefficient of variation was 2.5% for the HinfI/RsaI digest and 3.4% for the HphI/MnlI digest.

We present data from the HphI/MnlI digest, while results obtained with HinfI/RsaI digest can be found in the corresponding Supplementary (S) Material (see tables in the Supplementary Material available online at <http://dx.doi.org/10.1155/2014/403253>).

2.3. Fatigue {#sec2.3}
------------

Fatigue was measured by the Mob-T Scale based on questions about six mobility items ((a) rising from a chair or bed, (b) walking indoors, (c) getting outdoors, (d) walking outdoors in nice weather, (e) walking outdoors in bad weather, and (f) climbing stairs). Every activity was described relative to whether the respondents did or did not feel fatigued afterwards. The mobility-tiredness Scale (Mob-T) counts the number of activities managed without fatigue. The highest scale value thus describes no fatigue. The construct validity of the scale was tested by the Rasch model for item analysis, which showed that the scale had satisfactory homogeneity \[[@B19], [@B20]\]. The data have recently been reanalyzed using a new test based on the Rasch model on the assumption of equal item discrimination---with satisfactory results \[[@B21]\]. Reliability tests showed agreement from 94.3% to 98.3% and kappa values from 0.72 to 0.88 for the included items on intrarater and interrater tests \[[@B22]\]. As this measure of fatigue focuses on fatigue in performing certain activities it is likely that it reflects the physiologic and biologic consequences of doing these activities.

2.4. Covariates {#sec2.4}
---------------

Covariates of lifestyle, mental health, and aging-related somatic diseases were included as potential confounding factors since previous studies have shown that they might be associated with fatigue and LTL \[[@B10], [@B23]--[@B29]\].

### 2.4.1. Lifestyle {#sec2.4.1}

Smoking status was divided in never, former, and current smokers. BMI was deduced from self-reported height and weight. Physical activity was scored on a five-point scale deducted from self-reported level and frequency of physical activity. The answers were scored as follows: 0: "no physical activity," 1: "seldom low intensity physical activity," 2: "frequent low intensity physical activity," 3: "seldom high and frequent low intensity physical activity," and 4: "frequent high intensity physical activity."

### 2.4.2. Mental Health Status {#sec2.4.2}

Cognitive performance was scored by a cognitive composite score. This was evaluated by a battery of five brief cognitive tests, which were selected to be sensitive to age-related changes. The tasks included a verbal fluency test, forward and backward digit span, and immediate and delayed recall of a 12-item list. The standard scores for each task were summed to give an overall score. Higher cognitive composite scores indicated better cognitive function \[[@B30]\].

Depression symptomatology was assessed using an adaptation of the depression section of the Cambridge Mental Disorders of the Elderly Examination (CAMDEX) \[[@B31]\]. McGue and Christensen \[[@B15]\] factor analyzed the LSADT depression items identifying two factor scales (9-item affective and 8-item somatic scales). Because these scales were highly correlated (*r* \> 0.50), a 17-item total scale score has been defined \[[@B15]\]. Analyses reported here are based on the total scale score.

### 2.4.3. Somatic Disease {#sec2.4.3}

Cardiovascular disease included angina pectoris, heart failure, hypertension, irregular heart rhythm, and myocardial infarction. For diabetes and cancer any positive history is regarded as being a positive outcome and no distinction is done between type and duration. Rheumatologic disease covers the presence of either of the following conditions: rheumatic arthritis, osteoarthritis, and/or gout.

### 2.4.4. Statistical Methods {#sec2.4.4}

We applied a multiple regression modeling to test if fatigue was associated with LTL. A random intercept regression model was considered to account for nonindependence within pairs \[[@B32]\].

Possible association was further studied using an intrapair twin design in which difference in LTL was regressed on the difference in fatigue. This design enables us to control for age, sex, zygosity, and gel effect, as well as for early common environment and genetic factors. MZ twins share 100% of their genes while DZ twins only share 50%. If an association is attenuated among MZ twins it suggests genetic confounding. If an association is attenuated among MZ and DZ twins it suggests early environmental confounding.

A *P* value of 0.05 was chosen as significance level for all tests and the statistical analyses were done using STATA 11.1 (STATA Corp, College Station, TX, USA).

3. Results {#sec3}
==========

3.1. General Characteristics {#sec3.1}
----------------------------

A total of 439 twins representing 257 twin pairs were studied. 145 (33%) were men, and 294 (67%) were women; 235 (53.5%) came from a dizygotic twin pair (DZ) and 204 (46.5%) from a monozygotic twin pair (MZ). Descriptive statistics of participants are presented in [Table 1](#tab1){ref-type="table"}. The mean ages of the participants were 78.1 years for men (range 73--88) and 78.5 years for women (range 73--94).

Women were found to have longer LTL than men (age adjusted: 4.65 kb and 4.46 kb, resp.). The age-related attrition in this population was 0.020 kb per year. There was no significant difference in fatigue score between men and women. Fatigue was inversely correlated with age (*R* = −0.25, *P* \< 0.001), that is, the higher the age the more fatigued (lower score).

The association between the examined covariates and, respectively, LTL and fatigue is presented in [Table 2](#tab2){ref-type="table"}. Only smoking and depression symptomatology were significantly associated with LTL, while BMI, physical activity, cognitive function, depression symptomatology, and rheumatic disease were significantly associated with fatigue.

3.2. Multivariate Analysis {#sec3.2}
--------------------------

The regression model revealed a positive association between LTL and fatigue when adjusting for effects of sex and age. For every unit increase in fatigue score, LTL increased by 0.038 kb after adjustment for sex and age (*P* = 0.023; [Table 2](#tab2){ref-type="table"}), which is equivalent to two years of age-related LTL attrition. There was no effect of zygosity nor was there an interaction effect of sex and age (data not shown) on the association. Hence, the association between fatigue and LTL was similar for each gender and zygosity.

The examined lifestyle factors had a minimal effect on the association between LTL and fatigue ([Table 3](#tab3){ref-type="table"}, model 3), diminishing the association coefficient from 0.038 to 0.032. Including mental health in the model ([Table 3](#tab3){ref-type="table"}, model 4) only slightly attenuated the association. However, inclusion of these covariates was not found to give a significantly better fit by a likelihood ratio test. Adjusting for somatic diseases separately or jointly did not influence the association between LTL and fatigue ([Table 3](#tab3){ref-type="table"}, model 5).

Including all covariates, that is, sex, age, gel effect, zygosity, somatic diseases, mental health, and lifestyle resulted in slight attenuation of the association between LTL and fatigue ([Table 3](#tab3){ref-type="table"}, model 6) (*P* = 0.166). However, likelihood ratio test indicated that the optimal model of the LTL-fatigue association includes only sex and age (model 2).

The analyses were repeated in a subsample of the study population restricted to individuals below 80 years. The LTL-fatigue association was found to be stronger in this younger subpopulation.

3.3. Intrapair Analysis {#sec3.3}
-----------------------

87 pairs were intact and discordant for the fatigue score. The intrapair analysis confirmed that for every one unit change in fatigue score, LTL differed by 0.039 kb (*P* = 0.054) within the pair ([Table 4](#tab4){ref-type="table"}). This effect was not significantly different between MZ and DZ twin pairs; however, the effect only reached significance in MZ twin pairs.

The association was attenuated when including lifestyle factors from Coef = 0.039 to Coef = 0.030 due to a small confounding effect of smoking and physical activity not seen in the regression analysis. Likelihood ratio test suggested the inclusion of smoking in the model. Also inclusion of depression symptoms provided a better fit of the data but hardly influenced the association (Coef = 0.036, *P* = 0.097) (data not shown).

3.4. Results from HinfI/RsaI Digest {#sec3.4}
-----------------------------------

This subpopulation consisted of 377 individuals representing 219 twin pairs. There was no noteworthy difference on the demographics of two populations (Table S1). There were similar associations between the examined covariates and, respectively, LTL and fatigue (Table S2).

The association with fatigue was of lesser magnitude and no longer reached significance (Table S3, model 2), neither for the younger subpopulation. Likelihood ratio test showed that the inclusion of lifestyle factors (especially smoking) as well as depression symptomatology had a better fit of data. Including these factors completely attenuated the association (Coef = 0.005, *P* = 0.846).

The intrapair analyses were in agreement with findings from the HphI/MnlI digest, however not significant, and could mostly be attributed to physical activity and smoking, as well as depression symptomatology.

4. Discussion {#sec4}
=============

In this study we observed an association between fatigue and LTL in nondisabled older twins. Previous studies have found fatigue to be related to onset of several adverse health outcomes \[[@B33]\], also when adjusted for multiple covariates. The predictive value of fatigue has been especially strong in nondisabled older persons and in persons without cardiovascular disease, indicating that fatigue may be an early marker of the aging process, before the onset of diseases and disability. We have earlier shown that LTL was related to physical ability, measured by a self-reported strength scale, in a study population of 70--93-year-old participants in the LSADT study \[[@B14]\]. The present study shows that LTL is associated with fatigue before the onset of disablement, thus suggesting that shortening of LTL is an early detectable event in this process.

Fatigue is a central symptom in many organic and psychiatric diseases. We have chosen to include four major aging-related diseases (CVD, diabetes, rheumatic disease, and cancer) as well as cognitive function as potential confounders since these have previously been suggested to be associated with LTL dynamics. However, we found no influence of either diseases or cognitive function on the LTL-fatigue association. Depression is a condition closely correlated with fatigue and is evidently associated with short LTL \[[@B34]\]. Thus, we considered depression a possible confounder. The inclusion of the available depression symptomatology score \[[@B15]\] slightly attenuated the association. It is likely that this finding is merely an over adjustment since the depression symptomatology score contains questions on feeling of lack of energy, which was highly correlated with fatigue (*R* = 0.323, *P* \< 0.001). The coexistence of fatigue and depression has previously been reported \[[@B35]\] and found to be associated with an increased risk of death in older adults \[[@B36]\], as has the coexistence of depression and other diseases predisposing to fatigue. A common inflammatory and oxidative stress pathway has been suggested \[[@B37]\], necessitating a clarification of this coexistence in future studies.

Of the included lifestyle factors, we found that only smoking had a slight effect on the association between LTL and fatigue. We have previously found that physical activity level was associated with LTL \[[@B14]\]. In this subpopulation the association was of the same magnitude but not significant. We suggest that this is simply due to lack of power and therefore chose to include physical activity as a possible confounder. However, physical activity seemed only to have an effect on the association when LTL was measured with the HInfI/RsaI digest. Smoking is therefore the only of the analyzed covariates that we suggest as a confounder to be included in the model besides sex and age.

A study by Woo et al. \[[@B12]\] found no association between frailty and LTL. The discrepancy is likely due to the focus on fatigue in the present study, while Woo and colleagues used a composite frailty index. Methodological variation could also have an impact, as Woo et al. reported a CV of 11.1% in their qPCR based method, while the CV of the TRF assay for this cohort was only 3.4%. Moreover, although our cohort was of limited size, we gained statistical power by exploiting the twin design.

Some limitations and strengths should be considered when interpreting the results. The low coefficient of variation is a strength to our study, as well as the twin design. We have included lifestyle factors and major aging-related diseases as covariates; in future studies inclusion of medications could be of value since these could contribute to fatigue. Various tools to evaluate fatigue exist \[[@B38]\]. Many scales have been suggested, some focusing on the severity of fatigue. Further different performance based measures are often used (e.g., an oxygen uptake measure or accelerometers) \[[@B39]\]. The used fatigue measure is reliable \[[@B1], [@B22]\] and has the advantage that it is a self-reported measure of fatigue in performing certain activities and is therefore likely to reflect the physiologic and biologic consequences of doing these activities \[[@B33]\]. Our study suggests a possible common physiological pathway between LTL attrition and fatigue; however, to establish a better insight into the dynamics in fatigue and cellular aging, future studies should examine changes over time of LTL and fatigue score in the same individuals.

5. Conclusion {#sec5}
=============

Overall, our findings indicate that LTL is associated with fatigue and that this cannot be explained by common lifestyle factors, aging-related diseases, or cognitive function. These findings largely agree with previous studies showing that fatigue is a strong indicator of adverse health outcomes in nondisabled older adults \[[@B33]\] and in middle-aged healthy men \[[@B17]\]. The findings are suggestive of oxidative stress and inflammation being underlying factors of fatigue and should spur the search for more biomarkers leading to a better understanding of the physiology behind fatigue.

Supplementary Material {#supplementary-material-sec}
======================

###### 

S-table 1-4 present data from the results obtained with HinfI/RsaI digest for which the inter-assay coefficient of variation was 3.4%.

###### 

Click here for additional data file.
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###### 

Descriptive statistics of the study population, including data on mean LTL, fatigue and lifestyle, mental health and somatic disease covariates.

  Characteristics                     Total (*N* = 439)   Female (*N* = 294)   Male (*N* = 145)   *P* value (sex diff.)
  ------------------- --------------- ------------------- -------------------- ------------------ -----------------------
  LTL (in kb)         Mean (SD)       4.59                4.67                 4.47               0.005\*
  Fatigue score       Mean (SD)       5.35                5.29                 5.46               0.170
   0                  *N* (%)         4 (0.9%)            4 (1.4%)             0 (0.0%)            
   1                  *N* (%)         3 (0.7%)            3 (1.0%)             0 (0.0%)            
   2                  *N* (%)         17 (3.9%)           11 (3.7%)            6 (4.1%)            
   3                  *N* (%)         21 (4.8%)           15 (5.1%)            6 (4.1%)            
   4                  *N* (%)         29 (6.6%)           19 (6.5%)            10 (6.9%)           
   5                  *N* (%)         58 (13.2%)          42 (14.3%)           16 (11.0%)          
   6                  *N* (%)         307 (69.9%)         200 (68.0%)          107 (73.8%)         
  Age                 Mean(SD)        78.4                78.5                 78.1               0.334
  Zygosity            MZ *N* (%)      204 (46.5%)         138 (46.9%)          66 (45.5%)          
  DZ *N* (%)          235 (53.5%)     156 (53.1%)         79 (54.5%)                              
                                                                                                  
  Smoking             Never *N* (%)   154 (35.1%)         129 (43.9%)          25 (17.2%)          
  Former *N* (%)      155 (35.3%)     86 (29.3%)          69 (47.6%)                              
  Current *N* (%)     139 (29.6%)     79 (26.9%)          51 (35.2%)                              
  BMI                 Mean (SD)       24.13               23.65                25.09              \<0.001\*
   \<18.5             *N* (%)         25 (5.7%)           23 (7.8%)            2 (1.4%)            
   18.5--24.9         *N* (%)         236 (53.8%)         174 (59.2%)          62 (42.8%)          
   25--29.9           *N* (%)         157 (35.8%)         80 (27.2%)           77 (53.1%)          
   \>30               *N* (%)         17(3.9%)            13 (4.4%)            4 (2.8%)            
  Physical activity   Mean (SD)       2.52                2.52                 2.52               0.979
   0                  *N* (%)         62 (14.1%)          43 (14.6%)           19 (13.1%)          
   1                  *N* (%)         14 (3.2%)           9 (3.1%)             5 (3.4%)            
   2                  *N* (%)         152 (34.6%)         98 (33.3%)           54 (37.2%)          
   3                  *N* (%)         55 (12.9%)          40 (13.6%)           15 (10.3%)          
   4                  *N* (%)         156 (35.5%)         104 (35.4%)          52 (35.8%)          
                                                                                                  
  Cognitive comp.     Mean (SD)       1.46                1.63                 1.11               0.113
  Depression sympt.   Mean (SD)       20.76               20.87                20.54              0.434
                                                                                                  
  Rheumatic disease   No *N*          283                 172                  115                 
  Yes *N* (%)         156 (35.5%)     122 (41.5%)         34 (23.4%)                              
  CVD                 No *N*          280                 182                  98                  
  Yes *N* (%)         159 (36.2%)     112 (38.1%)         47 (32.4%)                              
  Cancer              No *N*          389                 258                  131                 
  Yes *N* (%)         50 (11.4%)      36 (12.2%)          14 (9.7%)                               
  Diabetes            No *N*          419                 280                  139                 
  Yes *N* (%)         20 (4.6%)       14 (4.8%)           6 (4.1%)                                

\*Significant difference between sexes. ^*τ*^The *P* value for sex-differences has been adjusted for age.

LTL: leukocyte telomere length; CVD: cardiovascular disease; MZ: monozygotic twins; DZ: dizygotic twins.

###### 

The association between covariates and, respectively, LTL, and fatigue.

  Covariates                       Association with LTL   Association fatigue                                                                                                                                           
  -------------------------------- ---------------------- --------------------- ------- ---------------- ------------------------ ----------- -------- ---------------- --------- ------------ ------------------------ -------------
  Fatigue (Score 0--6)             0.039                  0.006--0.071          0.019   **0.038** ^††^   **0.005--0.070**         **0.023**                                                                              
  Age                              −0.019                 −0.035--−0.003        0.018   **−0.20**        −**0.036--**−**0.004**   **0.012**   −0.041   −0.073--−0.009   0.012     −**0.040**   −**0.072--**−**0.008**   **0.014**
  Sex                                                                                                                                                                                                                    
   Male                            Ref                                                  Ref                                                   Ref                                 Ref                                    
   Female                          0.161                  0.032--0.290          0.014   **0.169**        **0.041--0.297**         **0.009**   −0.169   −0.426--0.088    0.197     −0.154       −0.408--0.099            0.233
  Zygosity                                                                                                                                                                                                               
   MZ                              Ref                                                  Ref                                                   Ref                                 Ref                                    
   DZ                              −0.027                 −0.150--0.097         0.672   −0.039           −0.159--0.081            0.530       −0.020   −0.263--0.223    0.871     −0.047       −0.286--0.192            0.700
  Geleffect                        0.007                  0.000--0.014          0.040   0.002            −0.008--0.011            0.688                                                                                  
                                                                                                                                                                                                                        
  Smoking                                                                                                                                                                                                                
   Never                           Ref                                                  Ref                                                   Ref                                 Ref                                    
   Former                          −0.076                 −0.172--0.021         0.124   −0.063           −0.160--0.035            0.206       −0.132   −0.408--0.144    0.349     −0.208       −0.490--0.074            0.148
   Current                         −0.127                 −0.234--−0.020        0.020   **−0.122**       **−0.230--−0.014**       **0.027**   −0.156   −0.448--0.135    0.293     −0.252       −0.547--0.043            0.095
  Physical activity (Score 0--4)   0.024                  −0.006--0.054         0.122   0.020            −0.011--0.049            0.213       0.344    0.266--0.423     \<0.001   **0.336**    **0.257--0.415**         **\<0.001**
  BMI                              −0.010                 −0.022--0.003         0.137   −0.010           −0.023--0.003            0.127       −0.039   −0.072--−0.006   0.019     **−0.052**   **−0.085--−0.018**       **0.002**
                                                                                                                                                                                                                        
  Cognitive function               0.014                  −0.000--0.027         0.053   0.011            −0.009--0.025            0.111       0.041    0.005--0.077     0.025     **0.038**    **0.002--0.074**         **0.037**
  Depression symptomatology        −0.012                 −0.022--−0.002        0.022   **−0.012**       **−0.022--−0.002**       **0.024**   −0.120   −0.145--−0.094   \<0.001   **−0.118**   **−0.143--−0.093**       **\<0.001**
                                                                                                                                                                                                                        
  Cancer                                                                                                                                                                                                                 
   No                              Ref                                                  Ref                                                   Ref                                 Ref                                    
   Yes                             −0.005                 −0.122--0.113         0.940   −0.010           −0.127--0.107            0.868       −0.230   −0.588--0.129    0.209     −0.236       −0.592--0.120            0.194
  CVD                                                                                                                                                                                                                    
   No                              Ref                                                  Ref                                                   Ref                                 Ref                                    
   Yes                             −0.009                 0.095--0.076          0.829   −0.013           −0.098--0.072            0.763       −0.173   −0.414--0.068    0.160     −0.167       −0.406--0.072            0.171
  Diabetes                                                                                                                                                                                                               
   No                              Ref                                                  Ref                                                   Ref                                 Ref                                    
   Yes                             0.001                  −0.191--0.192         0.997   0.006            −0.184--0.196            0.952       −0.297   −0.852--0.257    0.293     −0.266       −0.817--0.284            0.343
  Rheumatic                                                                                                                                                                                                              
   No                              Ref                                                  Ref                                                   Ref                                 Ref                                    
   Yes                             0.004                  −0.080--0.087         0.933   −0.011           −0.095--0.072            0.788       −0.414   −0.656--−0.179   0.001     **−0.419**   **−0.659--−0.179**       **\<0.001**

Bold values mark the significant adjusted coeffients.

^†^The coefficients shows the magnitude of the linear association between covariates and LTL respectively fatigue. First columns are raw data, while second columns are adjusted for sex and age.

^††^There is a significant association between LTL and fatigue when adjusting for age and sex. The coefficient of 0.038 tells that for every increase on the fatigue score (i.e. the less fatigued) the LTL is 0.038 kb longer.

###### 

The association between LTL and fatigue.

  --------------------------------------------------------------------------------------------------------------------
  Population                  Model 1\       Model 2\        Model 3\        Model 4\       Model 5\        Model 6\
                              Raw            Age, sex        Lifestyle       Mental         Somatic         Full
  ------------ -------------- -------------- --------------- --------------- -------------- --------------- ----------
  All \        Coef           0.039          0.038           0.032           0.032          0.038           0.026
  *N* = 439                                                                                                 

  CI 95%       0.006--0.071   0.005--0.070   −0.003--0.070   −0.002--0.067   0.005--0.071   −0.011--0.064   

  *P*-value    0.019          0.023          0.074           0.066           0.025          0.166           

                                                                                                            

  \<80 y \     Coef           0.050          0.051           0.044           0.051          0.050           0.044
  *N* = 315                                                                                                 

  CI 95%       0.007--0.093   0.008--0.094   −0.002--0.090   0.003--0.099    0.006--0.094   −0.007--0.095   

  *P*-value    0.024          0.019          0.058           0.037           0.025          0.093           
  --------------------------------------------------------------------------------------------------------------------

Model 1: raw model.

Model 2: adjusted for sex and age.

Model 3: as Model 2 including adjustment for lifestyle factors.

Model 4: as Model 2 including adjustment for mental health.

Model 5: as Model 2 including adjustment for somatic disease.

Model 6: full model that is as Model 2 including adjustment for lifestyle factors, mental health, somatic disease as well as zygosity and gel-effect.

###### 

Intrapair analysis.

  ------------------------------------------------------------------
                              All            MZ              DZ
  ----------- --------------- -------------- --------------- -------
  All \       Coef            0.039          0.057           0.026
  *N* = 174                                                  

  CI 95%      −0.001--0.079   0.007--0.107   −0.035--0.086   

  *P*-value   0.054           0.027          0.398           

                                                             

  \<80 y \    Coef            0.058          0.069           0.049
  *N* = 110                                                  

  CI 95%      0.003--0.112    0.002--0.138   −0.035--0.132   

  *P*-value   0.040           0.049          0.247           
  ------------------------------------------------------------------

The intrapair analysis is shown for the whole sample as well as for the younger subpopulation. Further the analysis has been run for only MZ and DZ twins respectively.

The simple model is intrinsically adjusted for sex, age, geleffect and zygosity due to the intrapair twin design.

LTL: leukocyte telomere length; MZ: monozygotic twins; DZ: dizygotic twins.

[^1]: Academic Editor: Gustavo Duque
